Key facts
- Vigonvita Life Sciences (HKG: 02630)’s last known valuation is $719.4M (Nov 2025).
- It has raised $74.0M; the latest was IPO ($75.5M) in Nov 2025.
- Status: Publicly Held.
- ·Watchlist + deal alerts for Vigonvita Life Sciences (HKG: 02630)
- ·The full record, as it builds
Funding rounds
No funding rounds for Vigonvita Life Sciences (HKG: 02630) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vigonvita Life Sciences (HKG: 02630)
Vigonvita Life Sciences Co Ltd biopharmaceutical company. It is engaged in the discovery, acquisition, development, and commercialization of small-molecule drugs in strategically focused therapeutic areas, namely neuropsychiatry, reproductive health, and viral infection. The company's core Products include LV232, for the treatment of depressive disorder, and TPN171, for the treatment of erectile dysfunction. The company's operations are located in the PRC and Uzbekistan. Revenue is generated from the out-licensing and the sales of its pharmaceutical products.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2013
- Employees
- 280
- Website
- vigonvita.cn/
- Ownership
- Publicly Held
Vigonvita Life Sciences (HKG: 02630) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vigonvita Life Sciences (HKG: 02630) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vigonvita Life Sciences (HKG: 02630) in its N-PORT filings yet. We sweep new filings monthly.